tcr-t cells

Cell therapyexperimental

Clinical trial activity

9 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Mar 29, 2018 (NCT04677088)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06748872Phase 1Jul 1, 2025MediGene
NCT07014878Phase 1Jun 30, 2025Government of China
NCT06094842Phase 1Mar 1, 2024Bristol-Myers Squibb, University of Washington
NCT06043713Phase 1Jan 1, 2024Affini-T Therapeutics, Inc., University of Washington
NCT05648994Early Phase 1 (Phase 1)Dec 31, 2022Fujian Medical University
NCT05357027Phase 1/Phase 2 (Phase 2)Aug 10, 2022Fudan University, TCRCure Biopharma Corp.
NCT06904859Early Phase 1 (Phase 1)Jan 1, 2019Shenzhen University
NCT03778814Phase 1Dec 1, 2018Guangzhou Medical University, Jinan University
NCT04677088Phase 1Mar 29, 2018Lion TCR Pte. Ltd., Sun Yat-Sen University
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of WashingtonAcademic/Hospital2212024
Affini-T Therapeutics, Inc.For profit1012024
Bristol-Myers SquibbFor profit1012024
Fudan UniversityAcademic/Hospital1012022
Fujian Medical UniversityAcademic/Hospital1112022
Government of ChinaGovernment1112025
Guangzhou Medical UniversityAcademic/Hospital1112018
Jinan UniversityAcademic/Hospital1012018
Lion TCR Pte. Ltd.For profit1012018
MediGeneFor profit1112025
Shenzhen UniversityAcademic/Hospital1112019
Sun Yat-Sen UniversityAcademic/Hospital1112018
TCRCure Biopharma Corp.For profit1112022
13 organizations
Page 1 / 1